2026 ACC/AHA Dyslipidemia Guideline: A Practical Clinical Review
Clinical Practice Update — Risk Assessment, LDL-C Targets, Biomarkers, and Comparative Guidance from ACC/AHA, ESC/EAS, and NICE
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Risk assessment, LDL-C goals, novel biomarkers (Lp(a), apoB), and lipid-lowering therapy selection for primary and secondary prevention of ASCVD
- Target Audience
- Primary care physicians, internists, cardiologists, family medicine, residents, pharmacists
- Setting
- Outpatient primary care, cardiology clinic, hospital inpatient, post-ACS follow-up
- Source Evidence
- •2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (JACC, March 2026)
- •2025 ESC Focused Update on Management of Dyslipidaemias
- •2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
- •NICE CG181 — Cardiovascular Disease: Risk Assessment and Reduction
- •Landmark trials: FOURIER, ODYSSEY OUTCOMES, CLEAR OUTCOMES, REDUCE-IT, VESALIUS-CV
Key Clinical Takeaways
The 2026 ACC/AHA dyslipidemia guideline is the biggest shift in US lipid management since 2018. Here is what actually changes your clinic on Monday morning.
- 1Swap the Pooled Cohort Equations for PREVENT-ASCVD — it estimates both 10- and 30-year risk and is usable from age 30 → Risk Assessment
- 2Remember three LDL-C numbers: under 55 for very high-risk ASCVD, under 70 for other ASCVD, under 100 for intermediate primary prevention → Treatment Goals
- 3Measure Lp(a) at least once in every adult — it is now a Class I recommendation → Biomarkers
- 4Use the “CPR” framework for borderline or intermediate risk: Calculate, Personalize, Reclassify with CAC when needed → Primary Prevention
- 5If the patient is not at goal on a statin, add ezetimibe first; then escalate to a PCSK9 monoclonal antibody, bempedoic acid, or inclisiran → Nonstatin Cascade
- 6Check apoB in patients with diabetes, triglycerides above 200 mg/dL, or LDL-C already under 70 mg/dL — it catches residual risk that LDL-C misses → Biomarkers
- 7Bempedoic acid is now a Class I nonstatin option based on CLEAR OUTCOMES — useful in true statin intolerance → Nonstatin Cascade
- 8Consider icosapent ethyl for patients with persistent triglycerides of 135–499 mg/dL despite a statin, in line with REDUCE-IT → Triglycerides
- 9Start earlier — consider pharmacotherapy in young adults with LDL-C of 160 mg/dL or greater, or a strong family history of premature ASCVD → Primary Prevention
- 10The US, European, and UK frameworks diverge meaningfully on thresholds and targets — know which one applies where you practise → Comparative View
What’s Actually New — and Why It Matters
The 2026 document is not a light refresh of the 2018 cholesterol guideline. It has been retitled from “Blood Cholesterol” to “Dyslipidemia” to reflect a broader understanding of atherogenic risk beyond LDL-C alone — including triglyceride-rich remnant particles and Lp(a). Five practical shifts define the new document.
1. A new risk engine
The Pooled Cohort Equations, which have anchored US primary prevention since 2013, are retired. They are replaced by the PREVENT-ASCVD equations, which the AHA introduced in 2023 using contemporary cohorts. PREVENT is usable from age 30, provides both 10-year and 30-year risk estimates, omits race as a variable, and incorporates kidney function and metabolic health.
2. LDL-C numerical goals are back
The 2013 and 2018 ACC/AHA documents had largely abandoned specific LDL-C targets in favour of percentage reductions and statin intensity. The 2026 guideline restores numerical targets — explicitly aligning US practice with the direction European guidelines have taken for years.
3. Universal Lp(a) measurement
For the first time in a US guideline, every adult should have Lp(a) measured at least once in life. This genetically determined risk factor affects an estimated 20% of adults globally and can reclassify an otherwise average-risk patient into a high-risk category.
4. ApoB as a measurable target
Apolipoprotein B, which directly counts atherogenic particles rather than estimating their cholesterol content, enters the US guideline as a recommended measurement in selected groups — particularly when LDL-C is discordant with true risk (diabetes, hypertriglyceridemia, very low LDL-C).
5. An expanded toolbox of nonstatin agents
Since 2018, five new lipid-lowering therapies have arrived. Bempedoic acid, inclisiran, icosapent ethyl, evinacumab, and lomitapide now have defined roles, supported by outcomes data from CLEAR OUTCOMES, REDUCE-IT, and ongoing inclisiran programmes.
How Should You Assess Cardiovascular Risk Now?
Risk assessment is the doorway to every other decision in the 2026 ACC/AHA dyslipidemia guideline. The authors introduce a simple mnemonic — CPR — to walk through it: Calculate the risk score, Personalize with factors not captured by the equation, and Reclassify using CAC if the decision is still unclear.
Use the PREVENT-ASCVD equations to calculate 10-year and 30-year cardiovascular risk in adults aged 30 to 79 years without known ASCVD. Do not continue to use the Pooled Cohort Equations for new assessments.
Strong Rec High Evidence ACC/AHA 2026Personalize the risk estimate by considering risk enhancers the equations do not capture: family history of premature ASCVD, chronic inflammatory disease, South Asian ancestry, preeclampsia, metabolic syndrome, and elevated Lp(a).
Strong Rec Moderate Evidence ACC/AHA 2026Consider a coronary artery calcium (CAC) score in adults aged 40 and older (men) or 45 and older (women) when the decision to start lipid-lowering therapy remains uncertain after CPR steps one and two. A CAC of zero supports deferring pharmacotherapy in borderline or intermediate risk.
Moderate Rec Moderate Evidence ACC/AHA 2026| Risk Tier | 10-Year PREVENT Risk | Treatment Posture | What You Actually Do |
|---|---|---|---|
| Low | Below 3% | Lifestyle first | Counsel on diet, activity, sleep, tobacco. Reassess every 4–6 years. |
| Borderline | 3% to under 5% | LLT may be considered | Run through CPR. CAC can be decisive here. Shared decision-making is essential. |
| Intermediate | 5% to under 10% | LLT should be considered | Moderate-intensity statin typically appropriate. LDL-C goal under 100 mg/dL. |
| High | 10% or higher | LLT recommended | High-intensity statin. LDL-C goal under 70 mg/dL. Add nonstatin if not at goal. |
What Are the New LDL-C Targets?
The committee frames the new targets around three numbers to memorise: 55, 70, and 100 mg/dL. These apply to LDL-C; non-HDL-C goals are set 30 mg/dL higher at each tier. Percentage-reduction goals still matter — at least a 50% LDL-C reduction for high-risk patients — but the absolute targets now drive therapy intensification.
Target an LDL-C under 55 mg/dL (and non-HDL-C under 85 mg/dL) in patients with clinical ASCVD at very high risk of recurrent events.
Strong Rec High Evidence ACC/AHA 2026Target an LDL-C under 70 mg/dL (and non-HDL-C under 100 mg/dL) in patients with ASCVD who are not classified as very high risk.
Strong Rec High Evidence ACC/AHA 2026Aim for an LDL-C under 100 mg/dL in primary prevention patients at intermediate or high calculated risk. A minimum 30–49% reduction should be achieved in this group.
Strong Rec Moderate Evidence ACC/AHA 2026Consider pharmacotherapy in young adults (ages 20 to 39) with LDL-C of 160 mg/dL or greater, or with a strong family history of premature ASCVD, to reduce cumulative lifetime exposure to atherogenic lipoproteins.
Moderate Rec Moderate Evidence ACC/AHA 2026Which Nonstatin Drug, in What Order?
A maximally tolerated statin plus ezetimibe remains the backbone of therapy because these agents are cheap, oral, and familiar. The interesting change is that bempedoic acid, inclisiran, and PCSK9 monoclonal antibodies have all graduated from “consider” to clear Class I or IIa recommendations based on outcomes data accumulated since 2018.
Start a high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) as the first-line agent in patients with ASCVD or calculated 10-year PREVENT risk of 10% or greater.
Strong Rec High Evidence ACC/AHA 2026Add ezetimibe 10 mg daily as the first nonstatin agent when LDL-C remains above the tier-specific target on maximally tolerated statin therapy.
Strong Rec High Evidence ACC/AHA 2026Prescribe a PCSK9 monoclonal antibody (evolocumab or alirocumab) when LDL-C remains above goal on a statin plus ezetimibe, particularly in very high-risk ASCVD.
Strong Rec High Evidence ACC/AHA 2026Consider bempedoic acid 180 mg daily as an additional or alternative LDL-lowering agent in patients who are statin intolerant or who remain above target. CLEAR OUTCOMES demonstrated cardiovascular event reduction in statin-intolerant adults.
Strong Rec Moderate Evidence ACC/AHA 2026Consider inclisiran 284 mg subcutaneously (initial, 3 months, then twice yearly) when access, adherence, or intolerance precludes a PCSK9 monoclonal antibody. Outcome trials are ongoing.
Moderate Rec Low Evidence ACC/AHA 2026LDL-Lowering Agents: A Practical Drug-by-Drug Reference
| Drug | Typical LDL-C Reduction | Route & Frequency | Key Outcome Trial | Watch-Outs in Practice |
|---|---|---|---|---|
| Ezetimibe | 15–25% | Oral, once daily | IMPROVE-IT | Generic, well tolerated. Always the next step after maximally tolerated statin. |
| Bempedoic acid | 18–25% | Oral, once daily | CLEAR OUTCOMES | Avoid in gout (raises uric acid). Rare tendon rupture signal. No muscle side effects. |
| Evolocumab | 55–65% | SC every 2 or 4 weeks | FOURIER, VESALIUS-CV | Self-administered. Cost and prior authorisation can delay start by weeks. |
| Alirocumab | 55–60% | SC every 2 or 4 weeks | ODYSSEY OUTCOMES | Functionally interchangeable with evolocumab; choose by formulary coverage. |
| Inclisiran | 45–55% | SC every 6 months (after loading) | ORION-9/10/11 (CV outcome trial ongoing) | Clinician-administered — helpful for adherence-challenged patients. Outcomes data still awaited. |
| Evinacumab | ~50% (HoFH) | IV every 4 weeks | ELIPSE HoFH | Only for homozygous familial hypercholesterolaemia. Refer to a specialist lipid clinic. |
- Verify all doses and contraindications against current prescribing information and local formulary before prescribing.
- LDL-C reduction figures are on top of background statin therapy unless otherwise noted.
How Should You Use Lp(a) and ApoB?
Two biomarkers graduate to prominence in 2026. Lp(a) becomes a universal once-in-a-lifetime test, and apoB enters the US guideline as a secondary measurement in specific scenarios where LDL-C underestimates true atherogenic burden.
Measure Lp(a) at least once in every adult. No repeat testing is needed unless therapy targeting Lp(a) becomes available.
Strong Rec Moderate Evidence ACC/AHA 2026Interpret Lp(a) of 125 nmol/L or higher (roughly 50 mg/dL) as a risk-enhancing factor. Levels of 250 nmol/L or higher indicate approximately double the baseline ASCVD risk and should drive more intensive LDL-C lowering.
Moderate Rec Moderate Evidence ACC/AHA 2026Measure apoB in patients with triglycerides above 200 mg/dL, with diabetes, or with achieved LDL-C under 70 mg/dL, to identify residual atherogenic particle burden that LDL-C alone may miss.
Moderate Rec Moderate Evidence ACC/AHA 2026| Lp(a) Level | Implied ASCVD Risk | Recommended Action | Counselling Points |
|---|---|---|---|
| Under 75 nmol/L (~30 mg/dL) | Not meaningfully elevated | Proceed with risk-based management | No family cascade testing needed on this result alone |
| 125–250 nmol/L (50–100 mg/dL) | ~1.4x increase | Risk-enhancing factor; consider tighter LDL-C target | Discuss cascade testing of first-degree relatives |
| Over 250 nmol/L (~100 mg/dL) | Approximately doubled | Treat as high-risk; target LDL-C under 70 mg/dL even if 10-year risk looks moderate | Cascade test relatives. Discuss emerging Lp(a)-lowering agents in trials |
Clinical Decision Pathway
A practical, question-based walkthrough of how to apply the 2026 guidance to a single adult patient in front of you.
Monitoring and Follow-Up
One of the most common reasons patients fail to reach LDL-C goals is that nobody rechecks the lipid panel in time to escalate therapy. Here is a practical schedule.
| Parameter | When to Check | Action Threshold | Common Pitfalls |
|---|---|---|---|
| Lipid panel | 4–12 weeks after starting or changing LLT; then every 3–12 months | Above tier-specific LDL-C goal → intensify | Not rechecking — “set and forget” is the commonest reason for unmet goals |
| Lp(a) | Once in adulthood | At or above 125 nmol/L → treat as risk-enhancer | Repeating unnecessarily. Lp(a) is genetic and does not change meaningfully with lifestyle or statins. |
| Transaminases (ALT) | Baseline, then only if symptomatic | Above 3x upper limit of normal with symptoms → hold statin | Routine serial testing is no longer advised and wastes resources |
| CK (creatine kinase) | Only with new muscle symptoms | Over 10x ULN with symptoms → stop statin | Mild CK elevation without symptoms rarely requires stopping therapy |
| HbA1c | Annually in patients on statin without known diabetes | Rise above 6.5% → diagnose and manage new diabetes; continue statin | Small statin-associated HbA1c rise is real but does not outweigh CV benefit |
| Uric acid (on bempedoic acid) | Baseline and if gout flares | New gout → reassess therapy | Patients with prior gout should generally avoid bempedoic acid |
How Does This Compare to Other Guidelines?
Clinicians in North America, Europe, and the UK are working from meaningfully different frameworks. The 2026 ACC/AHA document has moved US practice closer to European norms on some points (LDL-C targets, Lp(a) screening) but retains US-specific features such as the PREVENT engine and the CPR decision framework.
A Side-by-Side Comparison on the Questions That Matter Most
| Clinical Question | ACC/AHA 2026 (US) | ESC/EAS 2019 + 2025 Update (Europe) | NICE CG181 (UK) | Where They Diverge |
|---|---|---|---|---|
| Risk calculator | PREVENT-ASCVD (10- and 30-year) | SCORE2 / SCORE2-OP (10-year fatal + non-fatal) | QRISK3 (10-year) | Each regional equation is calibrated to its own population — not interchangeable |
| Primary prevention threshold | 5% PREVENT (should consider); 3–5% (may consider) | Age-tiered SCORE2 thresholds; roughly 5% for middle age, 7.5% for 50–69 | 10% QRISK3 | NICE is the most conservative; US and Europe broadly aligned |
| LDL-C target, very high risk | Under 55 mg/dL (1.4 mmol/L) | Under 55 mg/dL + at least 50% reduction from baseline | Non-HDL-C reduction of at least 40%; no explicit LDL-C target | NICE prioritises percentage reduction; US and Europe prioritise absolute targets |
| First-line statin | Intensity-matched to risk (high intensity for ASCVD or 10%+ risk) | Highest tolerated dose to achieve target | Atorvastatin 20 mg (primary); atorvastatin 80 mg (secondary) | NICE specifies agent and dose; US and Europe specify intensity or target |
| Lp(a) screening | Universal, once in adulthood (Class I) | At least once in adulthood (Class IIa) | Not routinely recommended | NICE has not yet incorporated Lp(a); US now strongest endorsement |
| ApoB measurement | Recommended in select scenarios (diabetes, high TG, low LDL) | Recommended as alternative/equivalent to non-HDL-C | Not routinely recommended | Europe most liberal; NICE most restrictive |
| Bempedoic acid positioning | Class I (post CLEAR OUTCOMES) | Recommended when targets unmet on statin + ezetimibe | Technology appraisal TA694 — specific criteria for use | NICE access is gated by specific eligibility criteria |
| CAC scoring | Integral to the CPR framework | Considered in selected cases | Not routinely recommended for risk reclassification | US most enthusiastic; NICE most reserved on imaging |
Evidence in Context
Where the major guideline bodies agree, where they part ways, and what the underlying trials actually showed.
Where ACC/AHA, ESC/EAS, and NICE Broadly Agree
All three frameworks endorse statins as the backbone of lipid-lowering therapy, require a minimum LDL-C reduction target (typically 40–50% in high-risk groups), recommend ezetimibe as the first nonstatin step, and accept PCSK9 monoclonal antibodies when statin + ezetimibe is insufficient. All three also endorse aggressive secondary prevention — there is no serious disagreement that established ASCVD warrants intensive LDL-C lowering.
Where the Biggest Disagreements Remain
Primary prevention threshold: NICE intervenes at a 10% 10-year QRISK3 — roughly double the US and European thresholds. This reflects an explicit cost-effectiveness calculation built into NICE’s methodology.
Absolute vs relative targets: NICE continues to frame success as a percentage reduction in non-HDL-C, while ACC/AHA and ESC/EAS now align on absolute LDL-C targets.
Lp(a) and apoB: The 2026 ACC/AHA guideline is the most assertive on universal Lp(a) screening. NICE has not yet incorporated Lp(a) into primary care workflows.
The Trials That Drove the 2026 Changes
FOURIER and ODYSSEY OUTCOMES: Confirmed that adding a PCSK9 monoclonal antibody to statin therapy reduces major cardiovascular events in ASCVD, and that benefit scales with the achieved LDL-C — including values well below 40 mg/dL with no floor effect for safety.
CLEAR OUTCOMES: Demonstrated that bempedoic acid reduces cardiovascular events in statin-intolerant adults across primary and secondary prevention. This is the evidence base that lifted bempedoic acid from “may be considered” to a Class I role.
REDUCE-IT: Showed that icosapent ethyl in patients with persistent hypertriglyceridemia on statin therapy reduced composite cardiovascular events by roughly a quarter. The benefit was not replicated with other omega-3 preparations, which is why the guideline specifies IPE rather than fish oil generically.
VESALIUS-CV: Extended PCSK9 inhibitor benefit into primary prevention in high-risk adults without prior MI or stroke — a finding that already has editorialists arguing for collapsing the under-55 and under-70 targets into a single lower goal in future updates.
What the 2026 Guideline Does Not Settle
Lp(a)-specific therapy: Pelacarsen and olpasiran are in phase III trials. Until outcome data arrive, management of elevated Lp(a) remains indirect — tighten LDL-C and address other risk factors.
Extremely low LDL-C: Safety data below 20–30 mg/dL are reassuring but still accumulating. The guideline does not set a lower bound.
Cost and access: The gap between recommendation and real-world access remains wide for PCSK9 monoclonal antibodies and inclisiran, particularly outside high-income settings.
How to Read the Evidence Tags
Every recommendation in this article carries two tags indicating how strong the recommendation is and how robust the supporting evidence is. These are Medaptly’s own simplified interpretations for educational clarity.
Recommendation Strength
| Tag | What It Means | In Practice |
|---|---|---|
| Strong Rec | High-quality evidence broadly supports this action. Benefits clearly outweigh risks for most patients. | Standard practice. Most patients meeting the criteria should receive this intervention. |
| Moderate Rec | Evidence favours this action, though some uncertainty remains. | Most patients should receive this, but clinical context may justify a different decision in individual cases. |
| Conditional Rec | Benefit less certain. Right choice depends on patient circumstances, preferences, and risk profile. | Discuss with the patient. Use shared decision-making. |
| Against | Evidence shows no benefit, or the risks outweigh benefits. | Avoid. Document reasoning if considering in unusual circumstances. |
Evidence Quality
| Tag | What It Means | How Confident Can You Be? |
|---|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. | Very confident. Future research unlikely to change this substantially. |
| Moderate Evidence | Single RCT, large observational studies, or meta-analyses with limitations. | Reasonably confident. Direction likely correct; magnitude may be refined. |
| Low Evidence | Expert consensus, small studies, case series, or extrapolation. | Less certain. Best available guidance; may change as evidence matures. |
These are Medaptly’s simplified interpretations for educational clarity. For the full classification systems used by each source guideline, consult the original documents listed in References.
References
- 1.Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
- 2.Blumenthal RS, Morris PB, Gaudino M, et al. 2026 Guideline on the Management of Dyslipidemia. Circulation. Published online March 13, 2026. doi:10.1161/CIR.0000000000001423
- 3.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
- 4.NICE Clinical Guideline CG181. Cardiovascular disease: risk assessment and reduction, including lipid modification. National Institute for Health and Care Excellence. nice.org.uk/guidance/cg181
- 5.Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR OUTCOMES). N Engl J Med. 2023;388(15):1353–1364. doi:10.1056/NEJMoa2215024
- 6.Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
- 7.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. doi:10.1056/NEJMoa1812792
- 8.Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174